News

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Detailed price information for Rallybio Corporaton (RLYB-Q) from The Globe and Mail including charting and trades.